Molecular biology of beta-estradiol-estrogen receptor complex binding to estrogen response element and the effect on cell proliferation

Neuroendocrinology Letters

Volumn 34, Issue SUPPL. 2, 2013, Pages 123-129

  Heger, Zbynek ^a,b   Zitka, Ondrej ^a,b,c   Krizkova, Sona ^b,c   Beklova, Miroslava ^a   Kizek, Rene ^b,c   Adam, Vojtech ^b,c  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

Author keywords

DNA binding domain; Estradiol; Estrogen receptor; Estrogen response element; Ligand binding domain

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR;

BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; CELL PROLIFERATION; COMPLEX FORMATION; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENE MUTATION; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; PROTEIN CONFORMATION; REVIEW; TUMOR GENE;

ANIMALS; CELL PROLIFERATION; ESTRADIOL; GENE EXPRESSION REGULATION; HUMANS; MALE; PROTEIN BINDING; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS;

EID: 84893977298     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Abbondanza C, De Rosa C, D'arcangelo A, Pacifico M, Spizuoco C, Piluso G,, et al (2012). Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines. J Cell Physiol. 227: 964-975.
2. Acconcia F, Kumar R (2006). Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 238: 1-14. (Pubitemid 43851144)
3. Alimirah F, Peng XJ, Yuan L, Mehta RR, Von Knethen A, Choubey D, et al (2012). Crosstalk between the peroxisome proliferator-activated receptor gamma (PPAR gamma) and the vitamin D receptor (VDR) in human breast cancer cells: PPAR gamma binds to VDR and inhibits 1 alpha,25-dihydroxyvitamin D-3 mediated transactivation. Exp Cell Res. 318: 2490-2497.
4. Ascenzi P, Bocedi A, Marino M (2006). Structure-function relationship of estrogen receptor α and β: Impact on human health. Mol Asp Med. 27: 299-402. (Pubitemid 44255847)
5. Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, et al (2013). The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer. 13: 1-7.
6. Ballesteros-Gomez A, Rubio S, Perez-Bendito D (2009). Analytical methods for the determination of bisphenol A in food. J Chromatogr A. 1216: 449-469.
7. Bechi N, Sorda G, Spagnoletti A, Bhattacharjee J, Ferro EaV, Barbosa BD, et al (2013). Toxicity assessment on trophoblast cells for some environment polluting chemicals and 17 beta-estradiol. Toxicol Vitro. 27: 995-1000.
8. Billon-Gales A, Krust A, Fontaine C, Abot A, Flouriot G, Toutain C, Berges H, Gadeau AP, et al (2011). Activation function 2 (AF2) of estrogen receptor-alpha is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc Natl Acad Sci U S A. 108: 13311 -13316.
9. Bobowski M, Vincent A, Steenackers A, Colomb F, Van Seuningen I, Julien S, et al (2013). Estradiol Represses the G(D3) Synthase Gene ST8SIA1 Expression in Human Breast Cancer Cells by Preventing NF kappa B Binding to ST8SIA1 Promoter. PLoS One. 8: 1-12.
10. Boulay F, Perdiz D (2005). 17 beta-Estradiol modulates UVB-induced cellular responses in estrogen receptors positive human breast cancer cells. J Photochem Photobiol B-Biol. 81: 143-153. (Pubitemid 41722586)
11. Bovet C, Plet B, Ruff M, Eiler S, Granger F, Panagiotidis A, et al (2009). Towards high-throughput identification of endocrine disrupting compounds with mass spectrometry. Toxicol Vitro. 23: 704-709.
12. Brunello A, Borgato L, Basso U, Lumachi F, Zagonel V (2013). Targeted Approaches to Triple-Negative Breast Cancer: Current Practice and Future Directions. Curr Med Chem. 20: 605-612.
13. Ceylan U, Akhan SE, Bastu E, Gungor-Ugurlucan F, Iyibozkurt AC, Topuz S (2012). Comparison of tibolone and 17beta-estradiol administration on the expression of zonula ocdudens-1, ocdudin, glial fibrillary acidic protein and c-fos levels in the brain cortex and hippocampus of female rats. Neuroendocrinol Lett. 33: 505-510.
14. Chang HL, Chen CY, Hsu YF, Kuo WS, Ou G, Chiu PT, et al (2013). Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. Biochim Biophys Acta-Gen Subj. 1830: 4053-4064.
15. Chen HQ, Yang KH, Choi SY, Fischer JH, Jeong HY (2009). Up-Regulation of UDP-Glucuronosyltransferase (UGT) 1A4 by 17 beta-Estradiol: A Potential Mechanism of Increased Lamotrigine Elimination in Pregnancy. Drug Metab Dispos. 37: 1841-1847.
16. Chen YZ, Chen CM, Yang BL, Xu QH, Wu F, Liu F, et al (2011). Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett. 302: 63-68.
17. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, et al (2012). Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14: 1-15.
18. Chieffi P, Chieffi S (2013). Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview. J Cell Physiol. 228: 1641-1646.
19. Cirillo F, Nassa G, Taralla R, Stellato C, De Filippo MR, Arribrosino C, et al (2013). Molecular Mechanisms of Selective Estrogen Receptor Modulator Activity in Human Breast Cancer Cells: Identification of Novel Nuclear Cofactors of Antiestrogen-ER alpha Complexes by Interaction Proteomics. J Proteome Res. 12: 421-431.
20. Coughlan N, Thillainadesan G, Andrews J, Isovic M, Torchia J (2013). beta-Estradiol-dependent activation of the JAK/STAT pathway requires p/CIP and CARM1. Biochim Biophys Acta-Mol Cell Res. 1833: 1463-1475.
21. Dobrzycka KM, Townson SM, Jiang S, Oesterreich S (2003). Estrogen receptor corepressors - A role in human breast cancer? Endocrine-Rel Cancer. 10: 517-536. (Pubitemid 38094889)
22. Dunnwald LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 9: 1-10.
23. Endler A, Chen L, Zhang J, Xu GT, Shibasaki F (2012). Binding of the ER alpha and ARNT1 AF2 domains to exon 21 of the SRC1 isoform SRC1e is essential for estrogen- and dioxin-related transcription. J Cell Sci. 125: 2004-2016.
24. Eom M, Lkhagyadorj S, Oh SS, Han A, Park KH (2013). ROS1 Expression in Invasive Ductal Carcinoma of the Breast Related to Proliferation Activity. Yonsei Med J. 54: 650-657.
25. Ferrari N, Mcdonald L, Morris JS, Cameron ER, Blyth K (2013). RUNX2 in mammary gland development and breast cancer. J Cell Physiol. 228: 1137-1142.
26. Forma E, Brzezianska E, Krzeslak A, Chwatko G, Jozwiak P, Szymczyk A, et al (2013). Association between the c.*229C > T polymorphism of the topoisomerase II beta binding protein 1 (TopBP1) gene and breast cancer. Mol Biol Rep. 40: 3493-3502.
27. Gagne F, Smyth SA, Andre C, Douville M, Gelinas M, Barclay K (2013). Stress-related gene expression changes in rainbow trout hepatocytes exposed to various municipal wastewater treatment influents and effluents. Environ Sci Pollut Res. 20: 1706-1718.
28. Gaynor KU, Grigorieva IV, Allen MD, Esapa CT, Head RA, Gopinath P, et al (2013). GATA3 Mutations Found in Breast Cancers May Be Associated with Aberrant Nuclear Localization, Reduced Transactivation and Cell Invasiveness. Horm Cancer. 4: 123-139.
29. Gonugunta VK, Nair BC, Rajhans R, Sareddy GR, Nair SS, Vadlamudi RK (2011). Regulation of rDNA Transcription by Proto-Oncogene PELP1. PLoS One. 6: 1-9.
30. Gronemeyer H, Gustafsson JA, Laudet V (2004). Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov. 3: 950-964. (Pubitemid 39534319)
31. Han WD, Zhao YL, Meng YG, Zang L, Wu ZQ, Li Q, et al (2007). Estrogenically regulated LRP16 interacts with estrogen receptor a and enhances the receptor's transcriptional activity. Endocrine-Rel Cancer. 14: 741-753. (Pubitemid 350074063)
32. Heldring N, Isaacs GD, Diehl AG, Sun M, Cheung E, Ranish JA, et al (2011). Multiple Sequence- Specific DNA-Binding Proteins Mediate Estrogen Receptor Signaling through a Tethering Pathway. Mol Endocrinol. 25: 564-574.
33. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al (2007). Estrogen receptors: How do they signal and what are their targets. Physiol Rev. 87: 905-931. (Pubitemid 47084672)
34. Hodges LC, Cook JD, Lobenhofer EK, Li LP, Bennett L, Bushel PR, et al (2003). Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res. 1: 300-311. (Pubitemid 36292615)
35. Howdeshell KI, Wilson VS, Furr J, Lambright CR, Rider CV, Blystone CR, et al (2008). A mixture of five phthalate esters inhibits fetal testicular testosterone production in the Sprague-Dawiey rat in a cumulative, dose-additive manner. Toxicol Sci. 105: 153-165.
36. Jeffries MKS, Conoan NH, Cox MB, Sangster JL, Balsiger HA, Bridges AA, et al (2011). The anti-estrogenic activity of sediments from agriculturally intense watersheds: Assessment using in vivo and in vitro assays. Aquat Toxicol. 105: 189-198.
37. Jenkins S, Betancourt AM, Wang J, Lamartiniere CA (2012). Endocrine-active chemicals in mammary cancer causation and prevention. J Steroid Biochem Mol Biol. 129: 191-200.
38. Jeong KW, Kim K, Situ AJ, Ulmer TS, An WJ, Stallcup MR (2011). Recognition of enhancer element-specific histone methylation by TIP60 in transcriptional activation. Nat Struct Mol Biol. 18: 1358-1365.
39. Jeong KW, Chodankar R, Purcell DJ, Bittencourt D, Stallcup MR (2012). Gene-Specific Patterns of Coregulator Requirements by Estrogen Receptor-alpha in Breast Cancer Cells. Mol Endocrinol. 26: 955-966.
40. Jiang PP, Hu QP, Ito M, Meyer S, Waltz S, Khan S, et al (2010). Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc Natl Acad Sci USA. 107: 6765-6770.
41. Karmakar S, Foster EA, Smith CL (2009). Unique Roles of p160 Coactivators for Regulation of Breast Cancer Cell Proliferation and Estrogen Receptor-alpha Transcriptional Activity. Endocrinology. 150: 1588-1596.
42. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al (1995). Activation of the estrogen-receptor through phosphorylatin by mitogen-activated protein-kinase. Science. 270: 1491-1494.
43. Kim J, Park UH, Moon M, Urn SJ, Kim EJ (2013). Negative regulation of ER alpha by a novel protein CAC1 through association with histone demethylase LSD1. FEBS Lett. 587: 17-22.
44. Komm BS, Mirkin S (2013). Evolution of the tissue selective estrogen complex (TSEC). J Cell Physiol. 228: 1423-1427.
45. Lange A, Katsu Y, Miyagawa S, Ogino Y, Urushitani H, Kobayashi T, et al (2012). Comparative responsiveness to natural and synthetic estrogens of fish species commonly used in the laboratory and field monitoring. Aquat Toxicol. 109: 250-258.
46. Lattrich C, Stegerer A, Haring J, Schuler S, Ortmann O, Treeck O (2013). Estrogen receptor beta agonists affect growth and gene expression of human breast cancer cell lines. Steroids. 78: 195-202.
47. Lee HR, Jeung EB, Cho MH, Kim TH, Leung PCK, Choi KC (2013). Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors. J Cell Mol Med. 17: 1-11.
48. Liu R, Zhou JL, Wilding A (2004). Simultaneous determination of endocrine disrupting phenolic compounds and steroids in water by solid-phase extraction-gas chromatography-mass spectrometry. J Chromatogr A. 1022: 179-189. (Pubitemid 37431081)
49. Lonard DM, O'Malley BW (2006). The expanding cosmos of nuclear receptor coactivators. Cell. 125: 411-414.
50. Macon MB, Fenton SE (2013). Endocrine Disruptors and the Breast: Early Life Effects and Later Life Disease. J Mammary Gland Biol Neoplasia. 18: 43-61.
51. Macpherson L, Lo R, Ahmed S, Pansoy A, Matthews J (2009). Activation function 2 mediates dioxin-induced recruitment of estrogen receptor alpha to CYP1A1 and CYP1B1. Biochem Biophys Res Commun. 385: 263-268.
52. Mcdonnell DP, Wardell SE (2010). The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol. 10: 620-628.
53. McGlynn LM,Tovey S, Bartlett JMS, Doughty J, Cooke TG, Edwards J (2013). Interactions between MAP kinase and oestrogen receptor in human breast cancer. Eur J Cancer. 49: 1176-1186.
54. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, et al. (2013). Genotype in BRCA-associated Breast Cancers. Breast J. 19: 87-91.
55. Muyan M, Callahan LM, Huang YF, Lee AJ (2012). The ligand-mediated nuclear mobility and interaction with estrogen-responsive elements of estrogen receptors are subtype specific. J Mol Endocrinol. 49: 249-266.
56. Nie YF, Qiang ZM, Zhang HQ, Ben WW (2012). Fate and seasonal variation of endocrine-disrupting chemicals in a sewage treatment plant with A/A/O process. Sep Purif Technol. 84: 9-15.
57. Oh Y, Chung KC (2013). Zinc finger protein 131 inhibits estrogen signaling by suppressing estrogen receptor alpha homo-dimerization. Biochem Biophys Res Commun. 430: 400-405.
58. Ombra MN, Di Santi A, Abbondanza C, Migliaccio A, Avvedimento EV, Perillo B (2013). Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochim Biophys Acta-Gene Regul Mech. 1829: 480-486.
59. Patani N, Martin LA, Dowsett M (2013). Biomarkers for the clinical management of breast cancer: International perspective. Int J Cancer. 133: 1-13.
60. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, et al (2008). DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 319: 202-206.
61. Preda C, Ungureanu MC, Vulpoi C (2012). Endocrine disruptors in the environment and their impact on human health. Environ Eng Manag J. 11: 1697-1706.
62. Puzianowska-Kuznicka M, Pawlik-Pachucka E, Owczarz M, Budzinska M, Polosak J (2013). Small-Molecule Hormones: Molecular Mechanisms of Action. Int J Endocrinol. 2013: 1-21.
63. Qiang ZM, Nie YF, Ben WW, Qu JH, Zhang HQ (2013). Degradation of endocrine-disrupting chemicals during activated sludge reduction by ozone. Chemosphere. 91: 366-373.
64. Qin CX, Lan XL, He J, Xia XT, Tian YL, Pei ZJ, et al (2013a). An In Vitro and In Vivo Evaluation of a Reporter Gene/Probe System hERL/F-18-FES. PLoS One. 8: 1-8.
65. Qin F, Wang LH, Wang XQ, Liu SZ, Xu P, Wang HP, et al (2013b). Bisphenol A affects gene expression of gonadotropin-releasing hormones and type I GnRH receptors in brains of adult rare minnow Gobiocypris rarus. Comp Biochem Physiol C-Toxicol Pharmacol. 157: 192-202.
66. Shahmoradgoli M, Riazalhosseini Y, Haag D, Becker N, Hovestadt V, Heck S, et al (2013). Protein phosphatase 1, regulatory subunit 15B is a survival factor for ER-positive breast cancer. Int J Cancer. 132: 2714-2719.
67. Schneider J, Ruschhaupt M, Buness A, Asslaber M, Regitnig P, Zatloukal K, et al (2006). Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. Int J Cancer. 119: 2974-2979. (Pubitemid 44846253)
68. Srinivasan S, Nwachukwu JC, Parent AA, Cavett V, Nowak J, Hughes TS, et al (2013). Ligand-binding dynamics rewire cellular signaling via estrogen receptor-alpha. Nat Chem Blo.l 9: 326-332.
69. Swedenborg E, Ruegg J, Makela S, Pongratz I (2009). Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders. J Mol Endocrinol. 43: 1-10.
70. Tang XJ, Naveedullah, Hashmi MZ, Zhang H, Qian MR, Yu CN, et al (2013). A Preliminary Study on the Occurrence and Dissipation of Estrogen in Livestock Wastewater. Bull Environ Contam Toxicol. 90: 391-396.
71. Van't Veer LJ, Dai HY, Van De Vijver MJ, He YDD, Hart AaM, Mao M, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415: 530-536. (Pubitemid 34130608)
72. Van Duursen MBM, Smeets E, Rijk JCW, Nijmeijer SM, Van Den Berg M (2013). Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model. Toxicol Appl Pharmacol. 269: 132-140.
73. Wilson BJ, Giguere V (2008). Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer. 7: 1-8.
74. Wolinska-Witort E, Martynska L, Chmielowska M, Wasilewska-Dziubinska E, Bik W, Baranowska B (2012). The evaluation of estradiol and leptin action on the activity of the somatotropic and gonadotropic axes in peripubertal female rats. Neuroendocrinol Lett. 33: 138-148.
75. Yu EJ, Kim SH, Heo K, Ou CY, Stallcup MR, Kim JH (2011). Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor alpha activity and co-activator synergy. Nucleic Acids Res. 39: 6932-6943.
76. Zeng H, Wu JC, Bedford MT, Sbardella G, Hoffmann FM, Bi K, Xu W (2013). A TR-FRET-Based Functional Assay for Screening Activators of CARM1. ChemBioChem. 14: 827-835.